Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Business product launch

Teranga Pharma launches Drepaf sickle cell drug

Analysis based on 10 articles · First reported Aug 26, 2026 · Last updated Aug 26, 2026

Sentiment
60
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The launch of Drepaf could disrupt the African sickle cell treatment market by offering a cheaper local alternative to imported hydroxyurea, potentially reducing costs for healthcare systems and patients. This may pressure existing suppliers like those of Hydrea and Siklos to lower prices, while boosting Teranga Pharma's growth prospects and regional influence.

Pharmaceuticals Healthcare

Senegalese pharmaceutical firm Teranga Pharma has launched Drepaf, a generic hydroxyurea treatment for sickle cell disease, marking the first time this gold-standard medication is produced in Africa. The drug, available in adult and pediatric doses, aims to reduce painful crises and reliance on costly imports. Backed by 4 billion CFA ($7.1 million) in funding, Drepaf is already generating interest across West and Central Africa, with partnerships in Burkina Faso, Guinea, and Ivory Coast, and requests from the Democratic Republic of the Congo, Gabon, and Cameroon. The company, led by CEO Mouhamadou Sow, plans to meet demand across sub-Saharan Africa by 2030, strengthening regional pharmaceutical sovereignty. The launch addresses a critical shortage, as a 2023 study found frequent supply disruptions of hydroxyurea in 13 French-speaking African countries. Patient advocates like Magueye Ndiaye of the Senegalese Association for the Fight Against Sickle Cell Disease highlight the drug's affordability and improved access, particularly for children.

100 Teranga Pharma launched
70 Teranga Pharma expanded to Burkina Faso
70 Teranga Pharma expanded to Guinea
70 Teranga Pharma expanded to Ivory Coast
60 Teranga Pharma partnered with India
60 Teranga Pharma aims to meet
50 Teranga Pharma received requests from Gabon
50 Teranga Pharma received requests from Cameroon
priv
Teranga Pharma is the central actor, having developed and launched Drepaf, the first generic hydroxyurea produced in Africa. This positions the company as a key player in regional pharmaceutical sovereignty and could drive significant revenue growth.
Importance 100.0 Sentiment 80.0
cnt
Senegal is the home country of Teranga Pharma and the launch site of Drepaf. The event enhances Senegal's pharmaceutical industry and regional standing.
Importance 80.0 Sentiment 70.0
per
As CEO and a pharmacist, Mouhamadou Sow leads Teranga Pharma's initiative, personally advocating for the drug's benefits. His leadership is critical to the company's expansion strategy.
Importance 70.0 Sentiment 70.0
per
Magueye Ndiaye, president of the Senegalese Association for the Fight Against Sickle Cell Disease, endorses Drepaf, highlighting its affordability and improved access. His advocacy supports adoption and awareness.
Importance 50.0 Sentiment 60.0
cnt
India provides technical partnership to Teranga Pharma, helping ramp up production and supply. This collaboration strengthens India's role in African pharmaceutical markets.
Importance 50.0 Sentiment 60.0
ngo
The association, led by Magueye Ndiaye, promotes awareness and comprehensive care for sickle cell disease. It supports Drepaf as a significant step forward in patient care.
Importance 40.0 Sentiment 60.0
cnt
Burkina Faso is one of the first countries to partner with Teranga Pharma to receive Drepaf, improving access to affordable sickle cell treatment for its population.
Importance 40.0 Sentiment 60.0
cnt
Guinea is another early partner, set to benefit from Drepaf's availability, addressing a critical need for affordable treatment.
Importance 40.0 Sentiment 60.0
cnt
Ivory Coast is partnering with Teranga Pharma to distribute Drepaf, enhancing its healthcare capabilities for sickle cell patients.
Importance 40.0 Sentiment 60.0
ngo
The WHO recommends hydroxyurea as the gold standard treatment, lending credibility to Drepaf. Its endorsement supports the drug's adoption across Africa.
Importance 30.0 Sentiment 50.0
cnt
The DRC has requested Drepaf, indicating potential future supply, which could significantly improve treatment access in a high-burden country.
Importance 30.0 Sentiment 55.0
cnt
Gabon has requested Drepaf, showing interest in adopting the affordable treatment for its sickle cell patients.
Importance 30.0 Sentiment 55.0
cnt
Cameroon has requested Drepaf, potentially expanding access to affordable treatment in Central Africa.
Importance 30.0 Sentiment 55.0
curr
The West African Economic and Monetary Union — CFA franc is the currency used for Drepaf's pricing and funding, reflecting the economic context of the launch.
Importance 20.0 Sentiment 50.0
Senegal related ↔ India
Senegal related ↔ Burkina Faso
Senegal related ↔ Guinea
Senegal related ↔ Ivory Coast
India related ↔ Burkina Faso
India related ↔ Ivory Coast
Guinea related ↔ Ivory Coast
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.